|Bid||2.65 x 1000|
|Ask||2.70 x 800|
|Day's Range||2.60 - 2.83|
|52 Week Range||2.55 - 6.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.67|
MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.
MALVERN, Pa. and SAN DIEGO, Nov. 07, 2018 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.
PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary, today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million. The shares are expected to begin trading on the Nasdaq Global Market under the symbol “PHAS” on October 18, 2018, and the offering is expected to close on October 22, 2018, subject to customary closing conditions. Citigroup, Cowen and Stifel acted as joint book-running managers for the offering.
Clinical-stage biopharmaceutical company PhaseBio recently filed for an initial public offering. The stock is expected to trade on the Nasdaq Global Market under the ticker symbol “PHAS.” The Company Founded ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, ...